Pacira BioSciences Inc
Research Pacira BioSciences Inc (PCRX) on Bullrun: valuation model: 78.8% overvalued, market cap USD 987.24M, P/E 200.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPCRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal78.8% overvalued
- Market capUSD 987.24M
- P/E200.7
- Financial periodFY2025
- RevenueUSD 726.41M
- Revenue growth3.6%
- Net incomeUSD 7.00M
- Free cash flowUSD 136.66M
- Gross margin79.4%
Valuation Snapshot
Bullrun's latest valuation model marks Pacira BioSciences Inc as 78.8% overvalued; latest market cap is USD 987.24M; P/E is 200.7.
About Pacira BioSciences Inc
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain;
Frequently asked questions
Is Pacira BioSciences Inc overvalued or undervalued?
Bullrun's valuation model currently marks Pacira BioSciences Inc as 78.8% overvalued.
What is Pacira BioSciences Inc's market cap?
Pacira BioSciences Inc's market capitalization is USD 987.24M.
What is Pacira BioSciences Inc's P/E ratio?
Pacira BioSciences Inc's price-to-earnings (P/E) ratio is 200.7.
What does Pacira BioSciences Inc do?
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.